Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-03 17:45 |
Publication of the Number of Shares Composing the Share Capital and of the Tota…
|
English | 119.3 KB | ||
| 2023-04-03 17:45 |
PUBLICATION MENSUELLE DU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOT…
|
French | 118.9 KB | ||
| 2023-03-21 07:30 |
Nicox : Présentations de données supplémentaires sur le NCX 470 au prochain Con…
|
French | 90.6 KB | ||
| 2023-03-21 07:30 |
Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World …
|
English | 89.4 KB | ||
| 2023-03-20 07:30 |
Nicox : Résultats financiers de l’année 2022, point sur les prochaines étapes c…
|
French | 136.9 KB | ||
| 2023-03-20 07:30 |
Nicox Reports 2022 Financial Results and Updates Key Future Milestones
|
English | 113.6 KB | ||
| 2023-03-03 09:57 |
Franchissement de seuils
|
French | 336.3 KB | ||
| 2023-03-03 07:30 |
Nicox : Présentations à des conférences scientifiques
|
French | 204.5 KB | ||
| 2023-03-03 07:30 |
Nicox to Present at Upcoming Scientific Conferences
|
English | 203.8 KB | ||
| 2023-03-01 17:45 |
Nombre de droits de vote au 28 février 2023
|
French | 80.9 KB | ||
| 2023-03-01 17:45 |
Number of voting rights as of February 28, 2023
|
English | 80.4 KB | ||
| 2023-03-01 07:30 |
Nicox: Ordinary Shareholder Meeting of February 28, 2023 - Approval of all Reso…
|
English | 72.0 KB | ||
| 2023-03-01 07:30 |
Nicox : Assemblée Générale Ordinaire du 28 février 2023 – Approbation des résol…
|
French | 72.9 KB | ||
| 2023-02-13 17:45 |
Nicox’s Ordinary Shareholder Meeting to be held on February 28, 2023
|
English | 74.5 KB | ||
| 2023-02-13 17:45 |
Nicox : Assemblée Générale Ordinaire le 28 février 2023
|
French | 75.1 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
